Form 4: Vistagen Therapeutics CEO Shawn Singh Acquires Shares Through Employee Stock Purchase Plan

Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired 7,541 shares of common stock at $1.70 per share through the company's Employee Stock Purchase Plan.

Summary

• Shawn Singh, President and CEO, and a Director of Vistagen Therapeutics, Inc. (VTGN), acquired shares of the company's common stock.
• The transaction occurred on June 30, 2025.
• A total of 7,541 shares were acquired at a price of $1.70 per share.
• This acquisition was made under the Issuer's 2019 Employee Stock Purchase Plan, as amended.
• The transaction is exempt under SEC Rules 16b-3(c) and 16b-3(d).
• Following this transaction, Shawn Singh directly owns 18,028 shares of common stock and indirectly owns 20,875 shares through The 1997 Singh Family Trust.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive (President and CEO) through an employee stock purchase plan is generally viewed as a positive signal of confidence in the company's future, although the transaction size is relatively small compared to total shares outstanding.

Positives

• Insider acquisition of shares, which can signal management's confidence in the company's future prospects.
• The acquisition was made through an Employee Stock Purchase Plan, indicating participation in employee benefit programs.

Future Outlook

This Form 4 filing reports a past transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. It reflects an individual executive's participation in an employee stock purchase plan.

Comparison to Industry Standards

• This Form 4 filing is a standard regulatory disclosure for insider transactions and does not contain information for direct comparison to industry-specific financial or operational benchmarks. Insider purchases, such as this one by Shawn Singh, are common across industries and are generally viewed as a positive signal of management confidence, though the specific amount and context (ESPP) are particular to this transaction.

Related Party Transactions

• Acquisition of 7,541 shares of common stock by Shawn Singh, President and CEO, and Director, from Vistagen Therapeutics, Inc. under the company's 2019 Employee Stock Purchase Plan.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive indicator of management's belief in the company's value.
• Employees: The transaction highlights the existence and utilization of an Employee Stock Purchase Plan, which can be a positive for employee retention and alignment of interests.

Key Dates

Recommendation

Keywords

Vistagen Therapeutics, VTGN, Shawn Singh, Insider Trading, Form 4, Stock Acquisition, Employee Stock Purchase Plan, Common Stock, Beneficial Ownership